Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Barberan

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Drug Metabolism and Drug Interactions|December 14, 2011
Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug developmentXavier Boulenc, Olivier Barberan
Future Medicinal Chemistry|March 24, 2011
Drug repositioning using in silico compound profilingElodie Dubus, Ismail Ijjaali, Olivier Barberan, et al.
Bioorganic & Medicinal Chemistry|April 25, 2007
Assessing potency of c-Jun N-terminal kinase 3 (JNK3) inhibitors using 2D molecular descriptors and binary QSAR methodologyIsmail Ijjaali, François Petitet, Elodie Dubus, et al.
European Journal of Medicinal Chemistry|October 12, 2010
Knowledge-based analysis of multi-potent G-protein coupled receptors ligandsPatricia Faure, Elodie Dubus, Ismail Ijjaali, et al.
Journal of Medicinal Chemistry|October 13, 2006
Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the datasetJulien Burton, Ismail Ijjaali, Olivier Barberan, et al.
Expert Opinion on Drug Discovery|March 19, 2013
Development of an ADME and drug-drug interactions knowledge database for the acceleration of drug discovery and developmentFrançois Petitet, Olivier Barberan, Elodie Dubus, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 9, 2025
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injuryAyoOluwa O Olubamiwa, Jingyi Ma, Patrice Dehanne, et al.
Hepatology (Baltimore, Md.)|July 18, 2024
Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injuryAyoOluwa O Olubamiwa, Tsung-Jen Liao, Jinwen Zhao, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Drug Metabolism and Drug Interactions|December 14, 2011
Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug developmentXavier Boulenc, Olivier Barberan
Future Medicinal Chemistry|March 24, 2011
Drug repositioning using in silico compound profilingElodie Dubus, Ismail Ijjaali, Olivier Barberan, et al.
Bioorganic & Medicinal Chemistry|April 25, 2007
Assessing potency of c-Jun N-terminal kinase 3 (JNK3) inhibitors using 2D molecular descriptors and binary QSAR methodologyIsmail Ijjaali, François Petitet, Elodie Dubus, et al.
European Journal of Medicinal Chemistry|October 12, 2010
Knowledge-based analysis of multi-potent G-protein coupled receptors ligandsPatricia Faure, Elodie Dubus, Ismail Ijjaali, et al.
Journal of Medicinal Chemistry|October 13, 2006
Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the datasetJulien Burton, Ismail Ijjaali, Olivier Barberan, et al.
Expert Opinion on Drug Discovery|March 19, 2013
Development of an ADME and drug-drug interactions knowledge database for the acceleration of drug discovery and developmentFrançois Petitet, Olivier Barberan, Elodie Dubus, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 9, 2025
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injuryAyoOluwa O Olubamiwa, Jingyi Ma, Patrice Dehanne, et al.
Hepatology (Baltimore, Md.)|July 18, 2024
Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injuryAyoOluwa O Olubamiwa, Tsung-Jen Liao, Jinwen Zhao, et al.
Pageof 1